Literature DB >> 31969252

Low-grade serous ovarian cancer: State of the science.

Brian Slomovitz1, Charlie Gourley2, Mark S Carey3, Anais Malpica4, Ie-Ming Shih5, David Huntsman6, Amanda N Fader5, Rachel N Grisham7, Matthew Schlumbrecht8, Charlotte C Sun9, Jane Ludemann10, Gail Austin Cooney11, Robert Coleman12, Anil K Sood12, Haider Mahdi13, Kwong K Wong12, Allan Covens14, David M O'Malley15, Fabrice Lecuru16, Lauren P Cobb12, Thomas A Caputo17, Taymaa May18, Marilyn Huang8, John Siemon8, Marta Llauradó Fernández3, Isabelle Ray-Coquard19, David M Gershenson12.   

Abstract

In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial ovarian cancer; Low-grade serous carcinoma of the ovary; Low-grade serous carcinoma of the peritoneum

Year:  2020        PMID: 31969252     DOI: 10.1016/j.ygyno.2019.12.033

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).

Authors:  Lucia Musacchio; Daniela Califano; Michele Bartoletti; Laura Arenare; Domenica Lorusso; Nunzia Simona Losito; Gennaro Cormio; Stefano Greggi; Francesco Raspagliesi; Giorgio Valabrega; Vanda Salutari; Carmela Pisano; Anna Spina; Daniela Russo; Michele Del Sesto; Vincenzo Canzonieri; Francesco Ferraù; Gian Franco Zannoni; Vera Loizzi; Viola Ghizzoni; Claudia Casanova; Valentina Tuninetti; Monika Ducceschi; Vittoria Del Vecchio; Simona Scalone; Domenico Priolo; Francesco Perrone; Giovanni Scambia; Sandro Pignata
Journal:  Br J Cancer       Date:  2022-07-22       Impact factor: 9.075

Review 2.  New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review).

Authors:  Raluca Ana-Maria Mogos; Razvan Popovici; Adina Elena Tanase; Tudor Calistru; Paula Popovici; Mihaela Grigore; Alexandru Carauleanu
Journal:  Exp Ther Med       Date:  2022-05-04       Impact factor: 2.751

3.  Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.

Authors:  Dane Cheasley; Marta Llaurado Fernandez; Martin Köbel; Hannah Kim; Amy Dawson; Joshua Hoenisch; Madison Bittner; Derek S Chiu; Aline Talhouk; C Blake Gilks; Madawa W Jayawardana; Kathleen I Pishas; Anne-Marie Mes-Masson; Diane Provencher; Abhimanyu Nigam; Neville F Hacker; Kylie L Gorringe; Ian G Campbell; Mark S Carey
Journal:  NPJ Precis Oncol       Date:  2022-06-29

4.  mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.

Authors:  Scott E Jordan; Heba Saad; Alex Sanchez Covarrubias; John Siemon; J Matt Pearson; Brian M Slomovitz; Marilyn Huang; Andre Pinto; Matthew Schlumbrecht; Sophia Hl George
Journal:  Gynecol Oncol       Date:  2020-09-18       Impact factor: 5.482

Review 5.  Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research.

Authors:  Angiolo Gadducci; Stefania Cosio
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

6.  Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma.

Authors:  Renan Ribeiro E Ribeiro; Ashley Valenzuela; Lindsey Beffa; C James Sung; M Ruhul Quddus
Journal:  Gynecol Oncol Rep       Date:  2021-01-22

Review 7.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906

8.  Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma.

Authors:  Ming-Min Jiang; Fan Zhao; Tao-Tao Lou
Journal:  Int J Gen Med       Date:  2021-06-03

9.  Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum.

Authors:  David M Gershenson; Priya Bhosale; Rachel N Grisham
Journal:  Gynecol Oncol Rep       Date:  2020-11-02

10.  Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Authors:  Bethany M Barnes; Louisa Nelson; Anthony Tighe; George J Burghel; I-Hsuan Lin; Sudha Desai; Joanne C McGrail; Robert D Morgan; Stephen S Taylor
Journal:  Genome Med       Date:  2021-09-01       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.